Skip to main content

Table 4 OS of different risk groups of stage III-IV LCNEC and SCLC

From: Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer

 

Risk Group

High Risk

Low Risk

LCNEC

Median OS (95%CI, months)

5.0 (4.0—6.0)

12.0 (11.0—14.0)

6-month OS rate (95%CI)

41.3% (36.0—47.4)

73.9% (68.7—79.4)

1-year OS rate (95%CI)

14.9% (11.3—19.7)

48.1% (42.4—54.5)

2-year OS rate (95%CI)

3.5% (1.9—6.4)

25.4% (20.6—31.2)

3-year OS rate(95%CI)

1.4% (0.5—3.7)

14.8% (11.1—19.7)

SCLC

median (95%CI, months)

7.0 (7.0—7.0)

14.0 (13.0—15.0)

6-month OS rate (95%CI)

54.1% (53.0—55.3)

78.4% (77.0—79.8)

1-year OS rate (95%CI)

22.7% (21.8—23.7)

54.0% (52.4—55.7)

2-year OS rate (95%CI)

6.0% (5.5—6.6)

28.1% (26.7—29.7)

3-year OS rate (95%CI)

3.1% (2.7—3.5)

18.7% (17.4—20.1)

  1. Abbreviation: LCNEC large cell neuroendocrine carcinoma, SCLC small cell lung cancer, OS overall survival, HR hazard ratio, CI confidence interval